Sanofi said it will repurchase €5 billion ($5.2 billion) of stock and grow profits faster this year as the drugmaker pivots ...

Adding OTC Cialis to Opella’s portfolio would complement its existing portfolio of popular OTC brands such as antihistamine Allegra, non-opioid pain reliever Doliprane, stomach cramp reliever ...

Doliprane), Opella, which generated €1.271 billion in Q3. Due to legal, regulatory, operational costs, and more emphasis on R&D investments, Sanofi's FCF will likely be reduced in the near term.